PMID- 37563586
OWN - NLM
STAT- MEDLINE
DCOM- 20230814
LR  - 20231121
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Aug 11
TI  - Folate deficiency may increase the risk for elevated TSH in patients with type 2 
      diabetes mellitus.
PG  - 169
LID - 10.1186/s12902-023-01422-2 [doi]
LID - 169
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) and thyroid dysfunction (TD) are two 
      common chronic endocrine disorders that often coexist. Folate deficiency has been 
      reported to be related with the onset and development of T2DM. However, the 
      relationship between folate deficiency and TD remains unclear. This study aims to 
      investigate the association of serum folate with TD in patients with T2DM. 
      METHODS: The study used data on 268 inpatients with T2DM in the Beijing Chao-yang 
      Hospital, Capital Medical University from October 2020 to February 2021. Thyroid 
      stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), and 
      serum folate were measured with chemiluminescence immunoassay (CLIA), and folate 
      deficiency was defined as a serum folate concentration < 4.4 ng/mL. Ordinary 
      least squares regression models were used to assess the association of serum 
      folate with TSH concentration. Multivariable logistic regression models were 
      performed to explore the correlation of folate deficiency and the risk for 
      elevated TSH. RESULTS: 15.3% of T2DM patients had TD. Among those patients with 
      TD, 80.5% had elevated TSH. Compared with the normal-TSH and low-TSH groups, the 
      prevalence of folate deficiency was significantly higher in the elevated-TSH 
      group (P < 0.001). Serum folate level was negatively associated with TSH 
      (beta=-0.062, 95%CI: -0.112, -0.012). Folate deficiency was associated with the 
      higher risk for elevated TSH in patients with T2DM (OR = 8.562, 95%CI: 3.108, 
      23.588). CONCLUSIONS: A low serum folate concentration was significantly 
      associated with a higher risk for elevated TSH among T2DM patients.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Lin, Lin
AU  - Lin L
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Du, Yushan
AU  - Du Y
AD  - Institute of Reproductive and Child Health / National Health Commission Key 
      Laboratory of Reproductive Health, Peking University, Beijing, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking 
      University, Beijing, China.
FAU - Niu, Guanyu
AU  - Niu G
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Capital Medical University, Beijing, China.
FAU - Xia, Shuangbo
AU  - Xia S
AD  - Institute of Reproductive and Child Health / National Health Commission Key 
      Laboratory of Reproductive Health, Peking University, Beijing, China.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking 
      University, Beijing, China.
FAU - Liu, Jufen
AU  - Liu J
AD  - Institute of Reproductive and Child Health / National Health Commission Key 
      Laboratory of Reproductive Health, Peking University, Beijing, China. 
      liujufen@bjmu.edu.cn.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Peking 
      University, Beijing, China. liujufen@bjmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230811
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - Q51BO43MG4 (Thyroxine)
RN  - 0 (Thyroid Hormones)
RN  - 06LU7C9H1V (Triiodothyronine)
RN  - 9002-71-5 (Thyrotropin)
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Humans
MH  - Thyroxine
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Thyroid Hormones
MH  - Triiodothyronine
MH  - *Thyroid Diseases/complications
MH  - Thyrotropin
MH  - Folic Acid
PMC - PMC10416468
OTO - NOTNLM
OT  - Serum folate
OT  - Thyroid dysfunction
OT  - Thyroid stimulating hormone
OT  - Type 2 diabetes mellitus
COIS- The authors declare no competing interests.
EDAT- 2023/08/11 00:42
MHDA- 2023/08/14 06:41
PMCR- 2023/08/11
CRDT- 2023/08/10 23:41
PHST- 2022/11/17 00:00 [received]
PHST- 2023/07/21 00:00 [accepted]
PHST- 2023/08/14 06:41 [medline]
PHST- 2023/08/11 00:42 [pubmed]
PHST- 2023/08/10 23:41 [entrez]
PHST- 2023/08/11 00:00 [pmc-release]
AID - 10.1186/s12902-023-01422-2 [pii]
AID - 1422 [pii]
AID - 10.1186/s12902-023-01422-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2023 Aug 11;23(1):169. doi: 10.1186/s12902-023-01422-2.